文献速递内脏/肾动脉与血管畸形

腔内治疗对稳定症状性自发性肠系膜上动脉夹层患者临床结局的影响

The impact of endovascular treatment on clinical outcomes of stable symptomatic patients with spontaneous superior mesenteric artery dissection.
PubMed 文献 · J Vasc Surg · 2020-09-18

该单中心回顾性研究纳入94例经初始药物治疗成功的自发性肠系膜上动脉夹层患者,比较单纯药物与药物后腔内修复的结局;两组无主要不良事件生存率相似,但腔内组夹层重塑更完全且SMA狭窄或闭塞发生率更低。

要点

  • 初始药物治疗成功后,腔内治疗与单纯药物的主要不良事件免于生存率相似。
  • 腔内治疗组夹层完全或部分重塑比例高于保守组(81.1% vs 44.4%)。
  • 腔内治疗组免于SMA狭窄或闭塞优于保守组(log rank P=.046)。

核心结论

  • 初始药物治疗成功后,腔内治疗与单纯药物治疗的自发性SMAD患者主要不良事件免于生存率相似。
  • 腔内治疗与更高的夹层完全重塑率和更低的SMA狭窄或闭塞发生率相关。

研究设计与样本

  • 单中心回顾性分析,2007年3月至2019年8月纳入94例自发性SMAD且初始药物治疗成功的患者。

主要发现

  • 腔内组技术成功率为86.5%(32/37)。
  • 平均随访33.6±26.2个月(范围1-120个月)期间,9例(9.6%)出现腹痛复发,6例接受额外干预。
  • 腔内组完全或部分重塑比例高于保守组(22[81.1%] vs 24[44.4%];P<.0001)。
  • 腔内组夹层不变比例低于保守组(5[13.5%] vs 23[42.6%];P=.0001)。
  • 估计主要不良事件免于生存率在1、3、5年分别为95.6%、88.9%、85.4%。

关键数值与推荐

  • 腔内组技术成功率为86.5%(32/37)。
  • 腔内组免于SMA狭窄或闭塞优于保守组(log rank P=.046)。

临床怎么用

  • 对初始药物治疗成功的稳定症状性SMAD患者,可考虑腔内治疗以促进夹层重塑并降低SMA狭窄或闭塞风险。
  • 单纯药物治疗仍是可选策略,因两组主要不良事件免于生存率相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the efficacy and clinical outcomes of endovascular treatment for superior mesenteric artery dissection (SMAD) and its effect on superior mesenteric artery (SMA) remodeling compared with medical management alone after successful initial medical management. METHODS: In this retrospective analysis, all patients with spontaneous SMAD at a single institution were identified from March 2007 to August 2019. The primary outcomes were freedom from major adverse events (MAEs, a composite of dissection-related death, the recurrence of mesenteric ischemia symptoms, and a requirement for intervention). The secondary outcomes were morphologic remodeling of the dissections and stenosis or occlusion of the SMA. RESULTS: A total of 94 patients with SMAD who underwent successful initial medical management (91 males; mean age, 50.4 ± 6.3 years) were enrolled in the study. Fifty-seven (60.6%) received medical management alone, and 37 (39.4%) underwent endovascular repair after initial medical management. In the endovascular group, the technical success rate was 86.5% (32 of 37). During a mean follow-up period of 33.6 ± 26.2 months (range, 1-120 months), nine (9.6%) patients experienced a recurrence of abdominal pain, and six had additional interventions for SMAD. The patients in the endovascular group showed more complete or partial remodeling (22 [81.1%] vs 24 [44.4%]; P < .0001) or unchanged dissections (5 [13.5%] vs 23 [42.6%]; P = .0001) than those in the conservative group. Survival analysis showed that the estimated MAE-free survival rates were 95.6%, 88.9%, and 85.4% at 1, 3, and 5 years, respectively. There was a higher freedom from SMA stenosis or occlusion in the endovascular group (log rank P = .046). CONCLUSIONS: Endovascular treatment and medical management alone result in similar MAE-free survival for patients with SMAD after successful initial medical management. Moreover, endovascular therapy is associated with a higher complete remodeling rate and greater freedom from SMA stenosis or occlusion.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Gao P, Li G, Chen J, et al. The impact of endovascular treatment on clinical outcomes of stable symptomatic patients with spontaneous superior mesenteric artery dissection. J Vasc Surg. 2020. PMID: 32956796. doi:10.1016/j.jvs.2020.08.117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。